TOYIN MARCUS: Open Payments
NPI 1942831425 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,150 in 42 payments from 10 companies in 2025. Trend: 2023 $1,552 · 2024 $2,370 · 2025 $2,150
Food & beverage: $2,150
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 6 | $447 |
| E.R. Squibb & Sons, L.L.C. | 6 | $349 |
| Teva Pharmaceuticals USA, Inc. | 10 | $327 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $198 |
| Otsuka America Pharmaceutical, Inc. | 7 | $175 |
| Alkermes, Inc. | 4 | $161 |
| ABBVIE INC. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Neurocrine BioSciences, Inc. | 1 | $122 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $122 |
Products named: INVEGA SUSTENNA, COBENFY, CAPLYTA, AUSTEDO XR, UZEDY, ABILIFY MAINTENA, VRAYLAR, Auvelity.
Industry payments across AZ — which companies pay providers there.
